Parsaclisib (INCB050465) (Synonyms: INCB050465) |
| Catalog No.GC32916 |
Parsaclisib (INCB050465) (INCB050465) es un inhibidor potente, selectivo y activo por vÍa oral de PI3Kδ, con una IC50 de 1 nM a ATP 1 mM. Parsaclisib (INCB050465) muestra una selectividad de aproximadamente 20 000 veces sobre otras isoformas de clase I de PI3K. Parsaclisib (INCB050465) se puede utilizar para la investigaciÓn de neoplasias malignas de células B recidivantes o refractarias.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1426698-88-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Parsaclisib is a potent and selective PI3Kδ inhibitor, with an IC50 of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases.
Parsaclisib (INCB050465) is a potent and selective PI3Kδ with an IC50 of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases. Parsaclisib displays significant activity with IC50 values ranging from 0.2 to 2 nM in B and T cell proliferation aaasys. Parsaclisib inhibits proliferation of several DLBCL and MCL cell lines in vitro (EC50 < 10 nM)[1].
[1]. Niu Shin, et al. Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. Cancer Research. 2015, Aug. 75(15).
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *